Overall Fundamental outlook

* IPCALAB makes the list of companies with the best fundamentals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

Ipca Laboratories Limited's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 2.627000
forwardPE 25.635342
debtToEquity 16.246000
earningsGrowth 0.136000
revenueGrowth 0.105000
grossMargins 0.655370
operatingMargins 0.132410
trailingEps 29.110000
forwardEps 47.850000

A current ratio of 2.627 for Ipca Laboratories Limited implies that the company has ample liquidity to meet its short-term debts. Ipca Laboratories Limited's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
IPCALAB's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
IPCALAB's low Debt-to-Equity ratio means the company is not highly leveraged. This suggests a sound financial position with minimal reliance on debt, reducing risk and ensuring greater financial flexibility, making it a more stable option for investors.
IPCALAB's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as IPCALAB's increasing profits and sales signal further growth in the near future.
IPCALAB's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights IPCALAB's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

Ipca Laboratories Limited's price projections have been gradually revised upward, reflecting increased confidence in the company's future performance. This trend suggests analysts expect Ipca Laboratories Limited to achieve greater success in the coming periods.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


IPCALAB experienced 1 sell transactions with market price of 1513.199951171875 per share.No sell transactions were carried out during the period under review.The higher volume of buys compared to sells near current Ipca Laboratories Limited price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


With analysts showing a buy bias for IPCALAB, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning IPCALAB as a safe and profitable place for investors to allocate their funds and seek growth.